5Landman D, Quale JM, Mayorga D, et al. Citywide clonal out- break of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned [J]. Arch Intern Med, 2002, 162 (13) : 1515 -1520.
6Chert W, Gao X, Tian Q, et al. A comparison of autofluorescence bronchoscopy and white light bronchoscopy in detection of lung cancer and preneoplastic lesions: a meta-analysis [ J ]. Lung Cancer, 2011, 73 (2): 183-188.
7倪语星,尚红.临床微生物学检验[M].5版.北京:人民卫生出版社,2012:143.
8Bou G, Cerver6 G, Domtnguez MA, et al. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter ban- mannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of beta- lactamases [J]. J Clin Microbiol, 2000, 38 (9) : 3299 -3305.
9Limansky AS, Mussi MA, Viale AM. Loss of a 29-kilogalton out- er membrane protein in Acinetobacter baumannii is associated with imipenem resistance [ J ]. J Clin Microbiol, 2002, 40 ( 12 ) : 4776 - 4778.
2Clinical and I.aboratory Standards Institute(CLSI). Perform ance standards for Antimicrobial susceptibility testing[S]. M100-S17, 2007.
3Clinical and Laboratory Standards Institute (CLSI). Perform anee standards for Antimicrobial susceptibility testing [S]. M100-S19,2009.
4Bratu S, I.andman D, Haag R, et al. Rapid spread of carbapenem resistant Klebsiella pneumoniae in New York City: anew threat to our antibiotic armamentarium[J]. Arch Int Meal.2005,165(12) :1430-1435.
5Endimiani A, Hujer AM, Perez F, et al. Characterization of blaKPC containing Klebsiella pneumoniae isolates detected in different institutions in the eastern USA [J]. J Antimierob Chemother, 2009, 63(3):427-437.
6Jeon BC, Jeong SH, Bae IK, et al. Investigation of a nosocomial outbreak of imipenem resistant Acinetobacter baumannii producing the OXA- 23 β- lactamase in Korea[J]. J Clin Microbiol, 2005, 43(5):2241 -2245.
7NaasT, LevyM, HirschauerC, et al. Outbreak ofcarbapen em resistant Acinetobacter baumannii producing the carbap enemase OXA- 23 in a tertiary care hospital of Pepcete, French Polynesta[J]. J Clin Mierohiol, 2005, 43 (9) : 4826- 4829.
8Waites KB, Dully LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and invitro activity of tigecycline, a new glycylcycline antimicrobial[J]. Antimicrob Agents Chemother, 2006,50(10):3479- 3484.
9Souli M, Kontopidou FV, Koratzanis E, et al. lnvitro activity of tigecycline against multiple-drug resistant, including pan resistant, Gram negative and Gram-positive clinical isolates from Greek hospitals[J]. Antimicrob Agents Chemother, 2006.50(9) :3166- 3169.
10Gordon NC, Warehan, DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline [J]. J Antimicrob Chemother, 2009, 63(4) :775-780.
3Rhomberg PR, Jones RN. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10year experience in the United States(1999-2008) [J]. Diagn Microbiol Infect Dis,2009,65(4):414-426.
